

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Hai-Tao Yang

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Li-Li Li

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Song-Nan Li

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Jin-Tao Wu

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Ke Chen

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Wei-Feng Song

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Guo-Bao Zhang

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Ji-Fang Ma

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Hai-Xia Fu

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Sheng Cao

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Chuan-Yu Gao

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: January,16th, 2022

Your Name: Juan Hu

Manuscript Title: MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing **pro-inflammatory** macrophage activation

Manuscript number (if known): No. CDT-21-743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).	

Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NO	
3	Royalties or licenses	NO	
4	Consulting fees	NO	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NO	
6	Payment for expert testimony	NO	
7	Support for attending meetings and/or travel	NO	
8	Patents planned, issued or pending	NO	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NO	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NO	
11	Stock or stock options	NO	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NO	
13	Other financial or non-financial interests	NO	

Please summarize the above conflict of interest in the following box:

This work was supported by the Joint Construction Project of Medical Science and Technology of Henan Province (Grant No. LHGJ20200072; LHGJ20200071; LHGJ20200077) and the Medical Science and Technology Project of Henan Province (No. SBGJ202002030).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.